Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine

Marc, Gonzalo Pérez; Álvarez-Paggi, Damián; Polack, Fernando P.

doi:10.1172/jci150135

Cited by 16 publications

(24 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, immunological naïve subjects should be prioritised for an additional vaccine administration. Studies reviewed in [ 17 ] indicated that one vaccine dose administration may sufficiently protect people who have recovered from COVID-19. However, few epidemiologic studies provided evidence of the benefit of vaccination for previously infected individuals as well.…”

Section: Discussionmentioning

confidence: 99%

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2

et al. 2022

View full text Add to dashboard Cite

Background COVID-19 vaccines have demonstrated effectiveness in reducing SARS-CoV-2 mild and severe outcomes. In vaccinated subjects with SARS-CoV-2 history, RBD-specific IgG and pseudovirus neutralization titers were rapidly recalled by a single BTN162b2 vaccine dose to higher levels than those in naïve recipients after the second dose, irrespective of waning immunity. In this study, we inspected the long-term kinetic and neutralizing responses of S-specific IgG induced by two administrations of BTN162b2 vaccine in infection-naïve subjects and in subjects previously infected with SARS-CoV-2. Methods Twenty-six naïve and 9 previously SARS-CoV-2 infected subjects during the second wave of the pandemic in Italy were enrolled for this study. The two groups had comparable demographic and clinical characteristics. By means of ELISA and pseudotyped-neutralization assays, we investigated the kinetics of developed IgG-RBD and their neutralizing activity against both the ancestral D614G and the SARS-CoV-2 variants of concern emerged later, respectively. The Wilcoxon matched pair signed rank test and the Kruskal–Wallis test with Dunn’s correction for multiple comparison were applied when needed. Results Although after 15 weeks from vaccination IgG-RBD dropped in all participants, naïve subjects experienced a more dramatic decline than those with previous SARS-CoV-2 infection. Neutralizing antibodies remained higher in subjects with SARS-CoV-2 history and conferred broad-spectrum protection. Conclusions These data suggest that hybrid immunity to SARS-CoV-2 has a relevant impact on the development of IgG-RBD upon vaccination. However, the rapid decay of vaccination-elicited antibodies highlights that the administration of a third dose is expected to boost the response and acquire high levels of cross-neutralizing antibodies.

show abstract

Section: Discussionmentioning

confidence: 99%

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Emerging data have demonstrated that one vaccine administration is sufficient to achieve high levels of anti-Spike immunity in people with a past SARS-CoV-2 infection. Indeed, it has been shown that following the first dose of mRNA vaccine, COVID-19 recovered subjects display high levels of anti-Spike IgG, including those with neutralizing activity [ 236 , 233 , 234 , 237 ]. Moreover, in recovered COVID-19 subjects the first vaccine dose maximizes the levels of circulating, Spike-specific, T and B cells [ 233 , 234 , 238 ].…”

Section: Heterogeneous Adaptive Immune Response To Sars-cov-2mentioning

confidence: 99%

Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion

Mazzoni

Salvati

Maggi

et al. 2021

Seminars in Immunology

View full text Add to dashboard Cite

One and half year following the occurrence of COVID-19 pandemic, significant efforts from laboratories all over the world generated a huge amount of data describing the prototypical features of immunity in the course of SARS-CoV-2 infection. In this Review, we rationalize and organize the main observations, trying to define a “core” signature of immunity in COVID-19. We identified six hallmarks describing the main alterations occurring in the early infection phase and in the course of the disease, which predispose to severe illness. The six hallmarks are dysregulated type I IFN activity, hyperinflammation, lymphopenia, lymphocyte impairment, dysregulated myeloid response, and heterogeneous adaptive immunity to SARS-CoV-2. Dysregulation and exhaustion came out as the trait d’union, connecting abnormalities affecting both innate and adaptive immunity, humoral and cellular responses.

show abstract

“…This is a perspective chiefly based on the reports that have suggested antibody quantitation could be a prevaccination screening strategy and specifically, a single dose of COVID-19 vaccine may likely suffice for the already SARS-CoV-2 infected cohort (1)(2)(3)(4)(5). These studies along with other findings similar to ours, have shown that the serological assessment of nucleocapsid (N)-and spike (S)-specific IgG antibody levels could differentiate vaccine-induced responses from those acquired following SARS-CoV-2 infection (1,6,7).…”

Section: Introductionmentioning

confidence: 99%

Silent SARS-CoV-2 Infections, Waning Immunity, Serology Testing, and COVID-19 Vaccination: A Perspective

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus causes a spectrum of clinical manifestations, ranging from asymptomatic to mild, moderate, or severe illness with multi-organ failure and death. Using a new machine learning algorithm developed by us, we have reported a significantly higher number of predicted COVID-19 cases than the documented counts across the world. The sole reliance on confirmed symptomatic cases overlooking the symptomless COVID-19 infections and the dynamics of waning immunity may not provide ‘true’ spectrum of infection proportion, a key element for an effective planning and implementation of protection and prevention strategies. We and others have previously shown that strategic orthogonal testing and leveraging systematic data-driven modeling approach to account for asymptomatics and waning cases may situationally have a compelling role in informing efficient vaccination strategies beyond prevalence reporting. However, currently Centers for Disease Control and Prevention (CDC) does not recommend serological testing either before or after vaccination to assess immune status. Given the 27% occurrence of breakthrough infections in fully vaccinated (FV) group with many being asymptomatics and still a larger fraction of the general mass remaining unvaccinated, the relaxed mask mandate and distancing by CDC can drive resurgence. Thus, we believe it is a key time to focus on asymptomatics (no symptoms) and oligosymptomatics (so mild that the symptoms remain unrecognized) as they can be silent reservoirs to propagate the infection. This perspective thus highlights the need for proactive efforts to reevaluate the current variables/strategies in accounting for symptomless and waning fractions.

show abstract

Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine

Cited by 16 publications

References 22 publications

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2

Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion

Silent SARS-CoV-2 Infections, Waning Immunity, Serology Testing, and COVID-19 Vaccination: A Perspective

Contact Info

Product

Resources

About